Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

FTH Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

Faeth Therapeutics, Inc.NASDAQ: FTH

Acquisitions (Net) · Q2 FY2026 · quarter ended Jun 2026

Acquisitions (net) outflow shrinks to $0

Q2 FY2026 acquisitions (net) was $0, compared with $210K a year earlier. Trailing-twelve-month acquisitions (net) was $6.46M. Over 3 fiscal years it compounded at +155.4% a year.

Context

  • Acquisitions (net) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly acquisitions (net) holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.62M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$250K— YoY
LTMJun 2026
$6.46M+2485.6% YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year———
3-year CAGR+155.4%——
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

USD · from the cash flow

Latest · FY2025
250K USD
Year-over-year change
—
4-year CAGR
-5.8%

Acquisitions (Net) vs competitors

How FTH compares with its peers on the latest reported figures

  • FTH's LTM Jun 2026 acquisitions (net) of $6.46M is the largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +2485.6% is the highest of 2, against a peer median of +100.0%.
FTH Competitors Peer median
Acquisitions (Net) for FTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FTHFaeth Therapeutics, Inc.LTM Jun 2026$6.46M +2485.6%+155.4%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$22K ———
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
NUVBNuvation Bio Inc.LTM Jun 2026$0 +100.0%—0.0%
VSTMVerastem, Inc.LTM Mar 2026$0 ——0.0%
KURAKura Oncology, Inc.LTM Mar 2026$0 ——0.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$0 ——0.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 ——0.0%
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
Peer median (excluding FTH) $0+100.0%—0.0%

Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Depreciation & Amortization685K1.35M1.35M1.32M139K
Deferred Income Tax19K0000
Stock-Based Compensation5.66M5.81M4.45M3.14M1.27M
Change in Working Capital117K1.01M(4.33M)(489K)(1.59M)
Accounts Receivables00000
Inventory00000
Accounts Payables(1.43M)2.02M(2.33M)(445K)233K
Other Working Capital1.54M(1.01M)(2M)(44K)(1.83M)
Other Non-Cash Items57K1.4M603K1.52M811K
Operating Cash Flow(30.26M)(39.03M)(32.02M)(24.67M)(20.45M)
Capital Expenditures(2.03M)(321K)(180K)(146K)(16K)
Acquisitions (Net)318K15K166K0250K
Purchases of Investments(183.67M)(46.87M)(21.15M)(44.6M)(25.16M)
Sales of Investments42.26M97.12M59.58M67.18M44.69M
Other Investing Activities00000
Investing Cash Flow(143.12M)49.95M38.41M22.44M19.77M
Debt Repayment(255K)(629K)(761K)(811K)(648K)
Common Stock Issued140.59M342K48K34K7K
Common Stock Repurchased00(10.38M)0(1K)
Dividends Paid00000
Other Financing Activities109K0(76K)(10K)(3K)
Financing Cash Flow163.94M(287K)(11.17M)(787K)(645K)
Effect of Forex Changes00000
Net Change in Cash(9.44M)10.64M(4.78M)(3.02M)(1.33M)
Free Cash Flow(32.29M)(39.35M)(32.2M)(24.82M)(20.47M)

Faeth Therapeutics, Inc.

NASDAQ:FTH

Intrinsic Alpha fair value

Locked

Current Price

$8.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.